Target Name: CD8B2
NCBI ID: G927
Other Name(s): CD8B2_HUMAN | CD8b pseudogene | CD8 antigen, beta polypeptide pseudogene | T-cell surface glycoprotein CD8 beta-2 chain | T-cell surface glycoprotein CD8 beta-2 chain isoform 1 precursor (isoform 1) | CD8b molecule pseudogene | CD8B2 variant 1 | CD8b2 molecule | CD8b2 molecule, transcript variant 1 | CD8BP | putative T-cell surface glycoprotein CD8 beta-2 chain

CD8B2: A promising drug target and biomarker for cancer treatment

CD8+ T cells are a crucial immune cell involved in fighting off infections and cancer. They are known for their ability to recognize and destroy infected or mutated cells, making them a potential target for cancer treatments. CD8B2, a protein that is expressed in high levels in the immune cells, has been identified as a promising drug target and biomarker for cancer treatment.

CD8B2's role in cancer biology

CD8B2 is involved in the immune response by helping to recognize and destroy infected or mutated cells. It is a key receptor for the antiviral drug lenofloxacin, which is used to treat HIV and some types of cancer. CD8B2 is also involved in the regulation of cell death, which is a critical part of the immune response.

CD8B2's potential as a drug target

CD8B2's potential as a drug target is due to its unique structure and the role it plays in the immune response. One of the key features of CD8B2 is its ability to interact with several different drugs, including lenofloxacin, which is an inhibitor of the enzyme Apo2L, a protein that is involved in cell death.

CD8B2's ability to interact with drugs has been shown to be associated with its potential as a drug target. Studies have shown that inhibiting Apo2L, which is regulated by CD8B2, can lead to increased activity of drugs that target CD8B2, such as lenofloxacin. This suggests that CD8B2 may be a useful target for cancer treatments that specifically target this protein.

CD8B2's potential as a biomarker

In addition to its potential as a drug target, CD8B2 has also been identified as a potential biomarker for cancer. The level of CD8B2 in immune cells, such as T cells, has been shown to be associated with the effectiveness of certain cancer treatments.

For example, studies have shown that higher levels of CD8B2 are associated with better outcomes in patients who are treated with the immunotherapy drug ipilimab. ipilimab is a monoclonal antibody that targets CD31, a protein that is expressed in immune cells, and is used to treat certain types of cancer.

Another study has also shown that CD8B2 levels are associated with increased activity of the immune system in patients who have been treated with the cancer drug adoptive T cell therapy. This suggests that CD8B2 may be a useful biomarker for evaluating the effectiveness of cancer treatments.

CD8B2's potential as a drug target and biomarker

CD8B2 is a protein that is expressed in high levels in the immune cells. Its unique structure and ability to interact with several different drugs make it a promising drug target for cancer treatments. Studies have shown that CD8B2's level is associated with the effectiveness of certain cancer treatments and may be a useful biomarker for evaluating the effectiveness of these treatments. Further research is needed to fully understand the role of CD8B2 as a drug target and biomarker for cancer treatment.

Protein Name: CD8b2 Molecule

Functions: Identifies cytotoxic/suppressor T-cells that interact with MHC class I bearing targets. CD8 is thought to play a role in the process of T-cell mediated killing (By similarity)

More Common Targets

CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16